# Pro Abtech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pro-abtech

- Industry: Biotechnology
- Headquarters: Gwangju, South Korea
- Website: www.proabtech.com
- Total disclosed funding: $8.4M
- Latest round: Series A (Oct 25, 2021)
- Investors on record: 6

## About

Founded in 2017 and based in Gwangju, South Korea, Pro Abtech operates as a biopharmaceutical development company that offers technology designed to overcome key limitations of improved biopharmaceutical drugs, including reduced activity, side effects, and low production yield.. In February 2024, Pro Abtech raised KRW 3 billion in venture funding from investors BNC Korea and Hanwha Investment & Securities. As of 2026, the company is led by its CEO Jung-haeng.

The company will utilize the February 2024 funding to work with Korea BNC to develop and commercialize treatments for obesity, diabetes, and cancer.

## Funding rounds

- Series A, Oct 25, 2021, $4.3M — Hana Securities, Golden Oak Investment, KUM OH ELECTRONICS CO., LTD.
- Series A, Aug 10, 2020, $4.2M — Albatross Investment, Widwin Investment, Hanwha Investment & Securities

## Investors

- Albatross Investment (https://capitalatlas.ai/funds/albatross-investment) — Series A
- Widwin Investment (https://capitalatlas.ai/funds/widwin-investment) — Series A
- Hanwha Investment & Securities (https://capitalatlas.ai/funds/hanwha-investment-securities) — Series A
- Hana Securities (https://capitalatlas.ai/funds/hana-securities) — Series A
- Golden Oak Investment (https://capitalatlas.ai/funds/golden-oak-investment) — Series A
- KUM OH ELECTRONICS CO., LTD. — Series A